Lymphoproliferative Disease Clinical Trials

2 recruiting

Lymphoproliferative Disease Trials at a Glance

7 actively recruiting trials for lymphoproliferative disease are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Houston, Atlanta, and Boston. Lead sponsors running lymphoproliferative disease studies include Pierre Fabre Medicament, Baylor College of Medicine, and Beijing Children's Hospital.

Browse lymphoproliferative disease trials by phase

Treatments under study

About Lymphoproliferative Disease Clinical Trials

Looking for clinical trials for Lymphoproliferative Disease? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lymphoproliferative Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lymphoproliferative Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

A Comprehensive Register Of Lymphoproliferative Disorders (ReLy)

Lymphoproliferative Disease
Fondazione IRCCS Policlinico San Matteo di Pavia9,000 enrolled1 locationNCT07519356
Recruiting
Not Applicable

Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis

EBV-associated T/NK-cell Lymphoproliferative DiseasesRefractory/Relapsed EBV-related Hemophagocytic LymphohistiocytosisLetermovir
Beijing Children's Hospital80 enrolled1 locationNCT07488728
Recruiting
Phase 1

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

LymphomaNon-Hodgkin's LymphomaHodgkin's Disease+1 more
Baylor College of Medicine136 enrolled3 locationsNCT01555892
Recruiting
Phase 2

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

LeiomyosarcomaSolid Organ Transplant ComplicationsLymphoproliferative Disorders+8 more
Pierre Fabre Medicament190 enrolled40 locationsNCT04554914
Recruiting
Phase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Phase 2

Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders

Epstein-Barr Virus-associated Lymphoproliferative DiseasesChronic Active Epstein-Barr Virus InfectionEBV Associated Lymphoma+1 more
Fudan University80 enrolled2 locationsNCT07381738
Recruiting

A Registry for People With T-cell Lymphoma

T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+4 more
Memorial Sloan Kettering Cancer Center1,000 enrolled26 locationsNCT05978141